Claims

1. Use of methazolamide in the manufacture of a medicament for effecting weight loss in a patient previously commenced on and undergoing treatment with an anti-diabetic agent.

2. The use according to claim 1 wherein the methazolamide is formulated for administration once the patient's blood glucose levels are stabilised by the anti-diabetic agent.

3. The use according to claim 1 or claim 2 wherein the medicament is for administration of methazolamide at a dosage rate of less than 100 mg per day.

4. The use according to claim 3 wherein the medicament is for administration of methazolamide at a dosage rate of about 90 mg, 80 mg or 75 mg per day.

5. The use according to claim 4 wherein the medicament is for administration at a dosage rate of about 80 mg per day by administration of a dosage of about 40 mg twice daily.

6. The use according to any one of claims 1-5 wherein the anti-diabetic agent is metformin.

7. The use according to any one of claims 1-6 wherein the methazolamide and anti-diabetic agents are formulated for oral administration, either simultaneously or separately.

8. The use according to any one of claims 1-7 wherein the patient has a body mass index (BMI) of at least 25.

9. The use according to any one of claims 1-8 wherein the patient has a waist measurement of greater than 94 cm (adult men) or greater than 80 cm (adult women).

10. Use of methazolamide in the manufacture of a medicament for effecting weight loss in

a patient previously commenced on and undergoing treatment with an anti-diabetic agent, wherein said medicament comprises methazolamide, together with one or more pharmaceutically acceptable additives, and an anti-diabetic agent.

11. Use of methazolamide in the manufacture of a combination medicament for effecting weight loss in a patient previously commenced on and undergoing treatment with an anti-diabetic agent, wherein said combination medicament comprises methazolamide and an anti-diabetic agent.

12. Use of a composition, comprising:

methazolamide in an amount of from about 80 mg to <100 mg;

metformin in an amount of 500 mg to 4,500 mg, and

one or more pharmaceutically acceptable additives, in the manufacture of a medicament for effecting weight loss in a patient previously commenced on and undergoing treatment with an anti-diabetic agent.

13. Use of a combination, comprising:

methazolamide in an amount of from about 80 mg to <100 mg, and

metformin in an amount of 500 mg to 4,500 mg, in the manufacture of a medicament for effecting weight loss in a patient previously commenced on and undergoing treatment with an anti-diabetic agent.

14. The use of claim 12 or claim 13, wherein the amount of methazolamide is 80 mg.

15. The use according to any one of claims 12 to 14, wherein the medicament is a single daily dose form.

16. The use according to any one of claims 12 to 14, wherein the medicament is a divided daily dose form.

17. The use according to any one of claims 12 to 16, wherein the amount of metformin is

selected from 1,250 mg and 1,545 mg.

18. The use according to any one of claims 12 to 16, wherein the amount of metformin is selected from 500, 750, 850 and 1,000 mg.

19. The use according to any one of claims 12 to 18, wherein the metformin is a pharmaceutically acceptable salt of metformin.

20. The use according to claim 19 wherein the metformin is metformin hydrochloride.

21. The use according to any one of claims 12 to 20, wherein the methazolamide and metformin are formulated together as an intimate composition.